Financial Performance Summary

Acutaas Chemicals Limited announced its consolidated financial results for the second quarter and half year ended September 30, 2026 (Q2 FY27 and H1 FY27).

Q2 FY27 Performance:

  • Revenue from Operations: ₹4,369 million, up 42.7% YoY (from ₹3,062 million in Q2 FY26) and up 32.5% QoQ (from ₹3,297 million in Q1 FY27)
  • Gross Profit: ₹2,715 million, up 59.0% YoY (from ₹1,707 million)
  • Gross Margin: 62.1%, improved from 55.8% in Q2 FY26 (637 bps expansion)
  • EBITDA: ₹1,760 million, up 84.6% YoY (from ₹953 million)
  • EBITDA Margin: 40.3%, improved from 31.1% in Q2 FY26 (920 bps expansion)
  • PAT: ₹1,231 million, up 71.4% YoY (from ₹719 million)
  • PAT Margin: 28.2%, improved from 23.5% in Q2 FY26 (472 bps expansion)

H1 FY27 Performance:

  • Revenue from Operations: ₹7,666 million, up 49.3% YoY (from ₹5,134 million in H1 FY26)
  • Gross Profit: ₹4,624 million, up 64.5% YoY (from ₹2,811 million)
  • Gross Margin: 60.3%, improved from 54.7% in H1 FY26 (560 bps expansion)
  • EBITDA: ₹2,890 million, up 97.7% YoY (from ₹1,462 million)
  • EBITDA Margin: 37.7%, improved from 28.5% in H1 FY26 (920 bps expansion)
  • PAT: ₹1,981 million, up 71.0% YoY (from ₹1,159 million)
  • PAT Margin: 25.8%, improved from 22.6% in H1 FY26 (320 bps expansion)

Business Highlights and Management Commentary

Mr. Naresh Patel, Executive Chairman & Managing Director, commented on the results:

  • Strong revenue growth of 42.7% YoY was led by continued momentum in the Pharmaceutical Intermediates business
  • Performance was partially offset by softer performance in the Specialty Chemicals segment
  • A significant milestone was achieved with the inauguration of the South Korea manufacturing facility ahead of schedule
  • The South Korea facility is equipped to produce high-purity chemicals used in photoresists, semiconductor packaging materials, etching materials and other semiconductor applications
  • This positions the company to capitalize on opportunities in the fast-growing semiconductor ecosystem

Revised Guidance

Based on improved revenue visibility and robust order pipeline, management revised upward its FY27 guidance:

  • Revenue growth guidance raised from 25% to approximately 30%
  • EBITDA margin guidance raised to 38-40% range

Company Overview

Acutaas Chemicals Limited is a specialty chemicals manufacturer serving industries including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. The company's core strength lies in research-driven development and manufacturing of advanced pharmaceutical intermediates used in both regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs). The company is expanding its portfolio to include high-value specialty chemicals for emerging technologies such as battery materials, semiconductor, and next-generation electronic applications.